Barrat J, Durand Chèné F
Nouv Presse Med. 1980 May 10;9(21):1491-4.
On the basis of a study involving 2338 months of treatment with progestational agents administered in sequential form from the 10th to the 25th day of the cycle, in women during the premenopausal period or suffering from benign or malignant breast pathology, the authors evaluated the contraceptive efficacy of this treatment. This efficacy was found to be good (Pearl index: 1 to 1,6%) with norsteroid progestational agents and inadequate with hydroxyprogesterone derivatives. It would thus appear possible to ensure coincidence of therapeutic action and contraception when norsteroids are used after the age of 40 (lower fertility) and/or when other methods are contraindicated.
基于一项涉及2338个周期月的研究,在绝经前期或患有良性或恶性乳腺疾病的女性中,从周期的第10天至第25天以序贯形式给予孕激素制剂进行治疗,作者评估了该治疗的避孕效果。结果发现,使用非甾体类孕激素制剂时避孕效果良好(Pearl指数:1%至1.6%),而使用羟孕酮衍生物时效果不佳。因此,在40岁以后(生育力较低)使用非甾体类药物和/或其他避孕方法禁忌时,似乎有可能确保治疗作用和避孕效果的一致性。